Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advaxis, Inc.
Advaxis Explores New Drug Licensing Opportunities
May 27th, 2009
Advaxis, Inc. (OTCBB: ADXS) has entered into a formal business agreement with the Sage Group to introduce potential partnership candidates and develop new licensing opportunities. The Sage Group is a leader in the provision of strategic and transactional consultancy services to US and European healthcare and life science companies advising on global strategic partnering opportunities. “With the increasing acceptance of our technology in the experimental medical community it is an opportune time to identify possible strategic relationships,” commented Advaxis CEO Thomas A. Moore. “As our current licensing negotiations develop, we also seek to find...
Source: Vaccine Weekly (2009-05-27)
|
